Format

Send to

Choose Destination
J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17.

Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.

Author information

1
Copenhagen Center for Glycomics and Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
2
Global Research, ALK-Abelló, Hørsholm, Denmark.
3
Department of Plant and Environmental Biology, Glyco section, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
4
Center for Cancer Immune Therapy, Department of Hematology, Herlev Gentofte Hospital, Herlev, Denmark.
5
Center for Cancer Immune Therapy, Department of Hematology, Herlev Gentofte Hospital, Herlev, Denmark; Department of Immunology and Microbiology and Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
6
Department of Immunology and Microbiology and Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
7
Copenhagen Center for Glycomics and Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: hhw@sund.ku.dk.
PMID:
30125661
DOI:
10.1016/j.jaci.2018.07.030

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center